Lanean...
Differential regulation of JAK/STAT-signaling in patients with ulcerative colitis and Crohn’s disease
In 2018, the pan-Janus kinase (JAK) inhibitor tofacitinib was launched for the treatment of ulcerative colitis (UC). Although tofacitinib has proven efficacious in patients with active UC, it failed in patients with Crohn’s disease (CD). This finding strongly hints at a different contribution of JAK...
Gorde:
| Argitaratua izan da: | World J Gastroenterol |
|---|---|
| Egile Nagusiak: | , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Baishideng Publishing Group Inc
2020
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7403801/ https://ncbi.nlm.nih.gov/pubmed/32821070 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v26.i28.4055 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|